US5776093A
(en)
*
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
US5260223A
(en)
*
|
1986-07-03 |
1993-11-09 |
President & Fellows Of Harvard College |
Methods for detection of human gamma, γ T cell receptor
|
EP0294703B1
(en)
*
|
1987-06-10 |
1995-05-10 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional antibody constructs and method for selectively destroying cell populations
|
JP2755395B2
(en)
*
|
1987-09-23 |
1998-05-20 |
ブリストル―マイアーズ スクイブ コムパニー |
Antibody heteroconjugate that kills HIV-infected cells
|
EP0334300A1
(en)
*
|
1988-03-21 |
1989-09-27 |
Neorx Corporation |
The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites
|
FI105320B
(en)
*
|
1988-04-04 |
2000-07-31 |
Oncogen |
Procedure for Preparation of Antibody Heteroconjugates for Use in Regulating Lymphocyte Activity and Diagnosis
|
EP0449879A1
(en)
*
|
1988-11-25 |
1991-10-09 |
Centocor, Inc. |
Heterobifunctional antibodies having specificity for platelets and thrombolytic agents
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5897861A
(en)
*
|
1989-06-29 |
1999-04-27 |
Medarex, Inc. |
Bispecific reagents for AIDS therapy
|
EP0739904A1
(en)
*
|
1989-06-29 |
1996-10-30 |
Medarex, Inc. |
Bispecific reagents for aids therapy
|
US5635177A
(en)
|
1992-01-22 |
1997-06-03 |
Genentech, Inc. |
Protein tyrosine kinase agonist antibodies
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
DE4419399C1
(en)
*
|
1994-06-03 |
1995-03-09 |
Gsf Forschungszentrum Umwelt |
Process for the preparation of heterologous bispecific antibodies
|
US5945311A
(en)
*
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
ES2169299T3
(en)
|
1996-09-03 |
2002-07-01 |
Gsf Forschungszentrum Umwelt |
PROCEDURE FOR THE DESTRUCTION OF CONTAMINANT TUMOR CELLS IN MOTHER CELL TRANSPLANTS USING SPECIFIC ANTIBODIES.
|
DK0826696T3
(en)
|
1996-09-03 |
2002-09-23 |
Gsf Forschungszentrum Umwelt |
Use of bi- and trispecific antibodies to induce a tumor immunity
|
AU2002323236A1
(en)
*
|
2001-08-17 |
2003-03-03 |
Gerlad Elfenbein |
In situ immunization
|
US7282205B2
(en)
|
2001-11-07 |
2007-10-16 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-hepatitis A virus antibodies
|
ES2528384T3
(en)
|
2001-12-12 |
2015-02-09 |
The Government Of The United States Of America, As Represented By The Secretary Department Of Healt |
Methods of using adenosine receptor inhibitors to enhance the immune response and inflammation
|
JP2006516883A
(en)
|
2002-09-19 |
2006-07-13 |
アメリカ合衆国 |
P. Arashi polypeptide, Capsicum fly polypeptide, and method of use
|
US7485306B2
(en)
|
2002-10-29 |
2009-02-03 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Lutzomyia longipalpis polypeptides and methods of use
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
JP5238936B2
(en)
|
2005-03-25 |
2013-07-17 |
ジーアイティーアール,インク. |
GITR binding molecules and uses thereof
|
CA2611519A1
(en)
|
2005-06-17 |
2006-12-28 |
Tolerx, Inc. |
Ilt3 binding molecules and uses therefor
|
EP2397853B1
(en)
|
2006-03-14 |
2014-01-15 |
Oregon Health and Science University |
Methods for detecting a mycobacterium tuberculosis infection
|
AU2007345745C1
(en)
|
2006-06-19 |
2013-05-23 |
Merck Sharp & Dohme Corp. |
ILT3 binding molecules and uses therefor
|
WO2008106551A2
(en)
|
2007-02-28 |
2008-09-04 |
The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. |
Brachyury polypeptides and methods for use
|
AU2008275589B2
(en)
|
2007-07-12 |
2013-11-21 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
EP2385371B1
(en)
|
2008-09-22 |
2014-10-22 |
Oregon Health and Science University |
Methods for detecting a mycobacterium tuberculosis infection
|
US8664183B2
(en)
|
2009-02-27 |
2014-03-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
SPANX-B polypeptides and their use
|
KR20120027055A
(en)
|
2009-06-26 |
2012-03-20 |
리제네론 파라마큐티칼스 인코포레이티드 |
Readily isolated bispecific antibodies with native immunoglobulin format
|
US9181306B2
(en)
|
2009-10-16 |
2015-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
US8961989B2
(en)
|
2009-11-20 |
2015-02-24 |
Oregon Health & Science University |
Methods for producing an immune response to tuberculosis
|
AU2011274423B2
(en)
|
2010-07-09 |
2016-02-11 |
Bioverativ Therapeutics Inc. |
Chimeric clotting factors
|
JP5997154B2
(en)
|
2010-08-16 |
2016-09-28 |
ノビミューン エスアー |
Method for producing multispecific multivalent antibody
|
WO2013119964A2
(en)
|
2012-02-08 |
2013-08-15 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
EP2689787A1
(en)
|
2010-09-03 |
2014-01-29 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
US9750806B2
(en)
|
2011-05-17 |
2017-09-05 |
Trion Research Gmbh |
Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
|
EP2524699A1
(en)
|
2011-05-17 |
2012-11-21 |
Trion Research GmbH |
Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
|
PT2717898T
(en)
|
2011-06-10 |
2019-05-20 |
Bioverativ Therapeutics Inc |
Pro-coagulant compounds and methods of use thereof
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
SG10201606158TA
(en)
|
2011-08-05 |
2016-09-29 |
Regeneron Pharma |
Humanized universal light chain mice
|
WO2013049362A2
(en)
|
2011-09-27 |
2013-04-04 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
|
JP6247226B2
(en)
|
2012-01-10 |
2017-12-13 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Improved transport of therapeutic molecules across the blood brain barrier
|
WO2013152352A1
(en)
|
2012-04-06 |
2013-10-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Live, attenuated rubella vector to express vaccine antigens
|
WO2014043518A1
(en)
|
2012-09-14 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
|
ES2633864T3
(en)
|
2012-09-24 |
2017-09-25 |
Ventana Medical Systems, Inc. |
Procedure to identify non-small cell lung cancer that responds to treatment using anaplastic lymphoma kinase (alk) as a marker
|
ES2639559T3
(en)
|
2012-12-28 |
2017-10-27 |
Ventana Medical Systems, Inc. |
Image analysis for breast cancer prognosis
|
WO2014164472A1
(en)
|
2013-03-10 |
2014-10-09 |
The Board Of Regents Of The University Of Texas System |
Biomarkers for chagas disease related cardiomyopathy
|
EP3065769A4
(en)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Procoagulant fusion compound
|
WO2015199976A1
(en)
|
2014-06-24 |
2015-12-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Target activated microdissection
|
AR101262A1
(en)
|
2014-07-26 |
2016-12-07 |
Regeneron Pharma |
PURIFICATION PLATFORM FOR Bispecific Antibodies
|
US10830678B2
(en)
|
2014-08-08 |
2020-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Photo-controlled removal of targets in vitro and in vivo
|
US11014088B2
(en)
|
2016-03-09 |
2021-05-25 |
The Board Of Regents Of The University Of Texas System |
Sensitive ELISA for disease diagnosis on surface modified poly(methyl methacrylate) (PMMA) microfluidic microplates
|
US12025615B2
(en)
|
2017-09-15 |
2024-07-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
WO2019073299A1
(en)
|
2017-10-10 |
2019-04-18 |
Medicenna Therapeutics, Inc. |
Il-4-fusion formulations for treatment of central nervous system (cns) tumors
|
EP4038222A4
(en)
|
2019-10-02 |
2023-10-18 |
Arizona Board of Regents on behalf of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
WO2024044687A1
(en)
|
2022-08-26 |
2024-02-29 |
Valo Health, Inc. |
Biomarker combinations for prognosis and management of diabetic retinopathy
|